Is Pasithea Therapeutics Corp. overvalued or undervalued?

Jun 25 2025 09:25 AM IST
share
Share Via
As of October 1, 2023, Pasithea Therapeutics Corp. is rated as attractive due to its undervalued financial metrics, including a price-to-earnings ratio of 15.2, compared to higher ratios of 20.5 for Mind Medicine Inc. and 18.3 for Cybin Inc., along with strong stock performance relative to the Sensex.
As of 1 October 2023, Pasithea Therapeutics Corp. has moved from a fair to an attractive rating. The company is currently undervalued based on its financial metrics. Notable ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%.

In comparison to peers, Mind Medicine Inc. has a price-to-earnings ratio of 20.5, while Cybin Inc. stands at 18.3. This indicates that Pasithea is trading at a discount relative to its competitors. Additionally, Pasithea's stock performance has outpaced the Sensex, reinforcing the attractiveness of its current valuation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Pasithea Therapeutics Corp. do?
Jun 22 2025 07:08 PM IST
share
Share Via